AstronauTx leads the way in a groundbreaking method for addressing neurodegenerative diseases. Its distinctive collection of small-molecule therapeutics aims to rectify dysregulated physiology, enhancing symptoms and altering the course of the disease. Here are details of AstronauTx’s latest funding round :
🚀 Launch
2019
🏭 Industry
Biotechnology
🧠Management
Dr Ruth McKernan (Founder), Dr David Reynolds (Founder), Dr Jamie Bilsland (Chief Scientif Officer), Dr Hannah Pearce (VP of Operations), Dr Keith Wafford (Head of Biology), Dr Daniel Hothersall (Senior Principal Scientist)
💸 Funding & Investors
| INVESTMENT (October 2023) | £48 million (Series A) |
| INVESTORS | led by the Novartis Venture Fund, the financing was supported by several global venture investors, including Brandon Capital, Bristol Myers Squibb, EQT Life Sciences from the LSP Dementia Fund and MPM Capital with support from the Dementia Discovery Fund. |
🎯 Funding purpose
Product development
🌐 Country HQ
UK (London)